COL18A1 and nasopharyngeal carcinoma: Moreover, endostatin treatment was associated with a lower incidence of nasopharyngeal mucosal necrosis/infection compared to literature reports for the treatment of stage III-IV NPC (31.8% vs. 40.6%, respectively).